Our understanding of the role of the cell cycle in neurodegenerative disease enable us to identify not just points of observation, e.g. the measures used in our diagnostic lymphocyte assay, but also potential points of intervention in the disease process, based on the role of cell cycle in the molecular patho-mechanism of AD. Based on this understanding, our IP covers the development of a pre-clinical drug screening tool. Our IP also covers the second use of over a dozen major drug families, whose cell cycle effects may be beneficial in the treatment of AD. We will use our screening tool, once developed, to examine the second use potential in AD of these drugs and others. By examining the cell cycle in neurones rather than lymphocytes, the effect of candidate compounds upon the G1/S transition in neurones can be investigated. Our proposed pre-clinical screen requires the insertion by homologous recombination of the SNP mutations we have identified in a particular human neuroblastoma line. The panel of mutants can then be validated against cell cycle drugs as a pre-clinical therapeutic screen. The screen could be used to identify new and existing drugs which may have efficacy against AD, some of which we have identified in our therapeutic strategy patent.